←
Ken Herrmann709 posts
Ken Herrmann avatar✓

Ken Herrmann ✓

@ProfKHerrmann

Nuc Med - Theranostics - Innovation. Embracing Change.

◷ Joined April 2022▧ 61 Photos and videos
JNM avatar
⟳ Ken Herrmann retweeted
JNM@JournalofNucMed·Jun 18

Sub–0.5-mm resolution allows the HR-PET to provide ¹⁸F-FITM uptake images of the mouse brain similar to those of the autoradiography, opening up new research opportunities for neurodegenerative diseases in mouse models. ow.ly/vAYk50ZcflQ #NuclearMedicine

Post attachment
UroToday.com avatar
⟳ Ken Herrmann retweeted
UroToday.com@urotoday·May 28

Understanding #RadiopharmaceuticalTherapy in #ProstateCancer: From Mechanism to Clinical Practice. Radiopharmaceutical therapy is rapidly reshaping the treatment landscape in advanced prostate cancer, bringing new opportunities—and new clinical questions—around patient selection, treatment sequencing, safety, mechanism of action, and future integration. In this exclusive UroToday clinical conversation series, leading experts in #MedicalOncology, #RadiationOncology, #NuclearMedicine, and TranslationalScience explore the evolving role of radiopharmaceutical therapy across the prostate cancer continuum. Through practical, peer-to-peer discussions, this series examines today’s treatment landscape, the biological and mechanistic distinctions between emerging approaches, real-world considerations for clinical decision-making, and where the next wave of innovation may take the field. #WatchNow > bit.ly/43grc3t #MichaelMorris @DrRanaMcKay @ProfKHerrmann @PrafulRavi1 @boothe_dustin @PhillipKooMD @nhbander @TDorffOnc @DrPhilKantoff @ConvergentRx #NealShore

Post attachment
Weijun Wei avatar
⟳ Ken Herrmann retweeted
Weijun Wei@Weijun_Wei89·May 12

Seeing is believing. CcRCC has the most complex metastatic patterns and many patients are misdiagnosed in routine clinical practice. CD70 PET is changing the landscape in China, many patients benefit from the imaging clinical trials. Need to develop CD70 therapeutic drugs!

Post attachment
Michael Hofman avatar
⟳ Ken Herrmann retweeted
Michael Hofman@DrMHofman·May 6

First images from the GE Omni 128 cm Total Body PET/CT 🚀 The new scanner detected a <5 mm local recurrence of prostate cancer missed by standard PSMA PET/CT - despite 79% shorter acquisition ⏱️ Delayed imaging boosted lesion uptake and informed dose-painted salvage RT 🎯 @JournalofNucMed @PeterMacCC @declangmurphy @_ShankarSiva jnm.snmjournals.org/content/…

1:10
OncoAlert avatar
⟳ Ken Herrmann retweeted
OncoAlert@OncoAlert·Apr 11

As if we needed another reason to go to #APCCC26 and #IPCS26 🇨🇭 A warm welcome to the #APCCC5k , a great way to start the day with a fun Run/Walk around Lake Lugano Switzerland. More details once you get to Lugano, but just reminding our colleagues...Bring your Running shoes, we will :-) See you There!! @Silke_Gillessen & @AOmlin @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun @UrsulaVogl Ping @nataliagandur @OncoAlert 🚨

0:16
OncoAlert avatar
⟳ Ken Herrmann retweeted
OncoAlert@OncoAlert·Apr 8

A reminder that #APCCC26 🇨🇭is coming in Late April and is OPEN TO EVERYONE, not just the Panel members and 👉️ REGISTER HERE: buff.ly/XpCWPdR 🚨 Enjoy 20% off when registering for both APCCC & IPCS 2026 Awarm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭 Event Details: 📍 Palazzo Congressi, Lugano, Switzerland 🎟️ Register here 🎓 Credits requests: SGU – SSU, SSMO, SRO, SGMN In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and researchers to address complex clinical questions where high-level evidence is limited. Over two days, the world’s leading experts will engage in high-level presentations, debates, and discussions to clarify and conceptualize the current landscape of care, with a focus on areas of controversy or uncertainty. The insights and consensus developed during the meeting are later published in European Urology, helping shape global standards. Creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! @Silke_Gillessen & @AOmlin @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun Ping @nataliagandur @OncoAlert 🚨

0:10
OncoAlert avatar
⟳ Ken Herrmann retweeted
OncoAlert@OncoAlert·Feb 27

The #OncoAlertTopTweet 🚨DAY ONE #GU26 Post: OncoAlert Just Published at @JCO_ASCO and out for #GU26 ABSTRACT 162 Poster Bd E17 Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 👉ascopubs.org/doi/10.1200/JCO… Here is Dr Michael Morris🇺🇸from @MSKCancerCenter to tell us more #ProstateCancer @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin @DrRanaMcKay Michael J. Morris @EAntonarakis @mishabeltran @drlouiseemmett @ProfKHerrmann @DrMHofman @JoshLangMD @CaPsurvivorship @Cpaller @cnsternberg

3:24
OncoAlert avatar
⟳ Ken Herrmann retweeted
OncoAlert@OncoAlert·Feb 27

The #OncoAlertTopTweet 🚨DAY ONE #GU26 Post: OncoAlert 🌐 Just Published at @JCO_ASCO and out for #GU26 Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 👉ascopubs.org/doi/10.1200/JCO… Here is Dr Andrew Armstrong🇺🇸 @AarmstrongDuke to tell us more #ProstateCancer @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin @DrRanaMcKay Michael J. Morris @EAntonarakis @mishabeltran @drlouiseemmett @ProfKHerrmann @DrMHofman @JoshLangMD @CaPsurvivorship @Cpaller @cnsternberg

2:19
OncoAlert avatar
⟳ Ken Herrmann retweeted
OncoAlert@OncoAlert·Feb 27

The #OncoAlertTopTweet 🚨DAY ONE #GU26 #APCCC26 🇨🇭 is open to everyone (not just panel members!) and is on April 30-May 2nd in Lugano EARLY REGISTRATION CLOSES February 28, 2026 👉 REGISTER HERE: buff.ly/XpCWPdR Join global experts in advanced #ProstateCancer at the Advanced Prostate Cancer Consensus Conference in Lugano (Palazzo Congressi) for two days of high-level debates addressing real-world clinical questions where evidence is limited, shaping future standards of care published in European Urology while creating opportunities for the next generation of leaders; enjoy 20% off when registering for both APCCC & IPCS 2026 @Silke_Gillessen @AOmlin @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrunPing @nataliagandur @OncoAlert

2:01